EDIT Editas Medicine, Inc. - Common Stock
$2,90
Kurs · Aug 18, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$2–$5
43% of range
Analystenbewertung
BUY
18 analysts
Kursziel
$6
+107% upside
P/E (TTM)
-1.6
ROE
-688.8%
Nettogewinnmarge
-395.0%
Über Editas Medicine, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Editas Medicine, ehemals Gengine, Inc., ist ein US-amerikanisches Biotechnologieunternehmen, das an Therapien auf der Grundlage der CRISPR/Cas-Methode forscht. Editas hat seinen Sitz in Cambridge, Massachusetts, und verfügt über Forschungseinrichtungen in Boulder, Colorado.
Mehr lesen
Editas Medicine, ehemals Gengine, Inc., ist ein US-amerikanisches Biotechnologieunternehmen, das an Therapien auf der Grundlage der CRISPR/Cas-Methode forscht. Editas hat seinen Sitz in Cambridge, Massachusetts, und verfügt über Forschungseinrichtungen in Boulder, Colorado.
## Geschichte
Editas wurde ursprünglich unter dem Namen Gengine, Inc. im September 2013 von Feng Zhang vom Broad Institute, Jennifer Doudna von der University of California, Berkeley, und George Church, David Liu und J. Keith Joung von der Harvard University gegründet und von Risikokapitalgebern finanziert; der Name wurde zwei Monate später in den aktuellen Namen Editas Medicine geändert. Doudna verließ das Unternehmen im Juni 2014 wegen rechtlicher Differenzen über das geistige Eigentum an Cas9.
Im August 2015 erhielt das Unternehmen in einer Finanzierungsrunde 120 Millionen US-Dollar von Bill Gates und weiteren Investoren. Am 2. Februar 2016 ging das Unternehmen an die Börse, wobei es 94 Millionen US-Dollar einnahm.
Im März 2020 hat Editas in Zusammenarbeit mit Allergan als erstes Unternehmen versucht, mit dem CRISPR-Verfahren DNA im Körper eines Menschen (in vivo) zu verändern. Im Rahmen der klinischen Studie erhielt ein Patient, der aufgrund der Leberschen kongenitalen Amaurose fast blind war, eine intravitreale Injektion mit einem harmlosen Virus, das die CRISPR-Anweisungen zur Genmanipulation trug. Auch an Therapien zur Heilung von Sichelzellkrankheit forscht das Unternehmen. Im Januar 2021 teilte das Unternehmen mit, dass es von der Food and Drug Administration die Genehmigung für Klinische Studien der Phase 1 erhalten habe.
== Einzelnachweise ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
EDIT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$2.90
Marktkapitalisierung
$284M
P/E (TTM)
-1.6
EPS (TTM)
$-1.80
Umsatz (TTM)
$41M
Dividendenrendite
—
ROE
-688.8%
Verschuldungsgrad
2.1
52W-Spanne
$2 – $5
EDIT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$41M
2016-12-31
→
2025-12-31
EPS
$-1.80
2019-12-31
→
2025-12-31
Freier Cashflow
$-166M
2016-12-31
→
2025-12-31
Margen
-395.0%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
EDIT
Peer-Median
P/E (TTM)
-1.6
17.4
P/S (TTM) (K/V (TTM))
7.0
52.3
P/B (K/B)
10.4
4.8
EV / EBITDA
-1.2
—
Price / FCF (Kurs / FCF)
-1.7
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
EDIT
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-394.9%
—
Net Profit Margin (Nettogewinnmarge)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
EDIT
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
2.1
—
Current Ratio (Liquiditätsgrad)
3.5
7.7
Quick Ratio
3.5
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
EDIT
Peer-Median
Revenue YoY (Umsatz YoY)
25.4%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
27.2%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
-14.9%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
EDIT
Peer-Median
EDIT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
18 Analysten
- Starker Kauf 4 22,2%
- Kauf 8 44,4%
- Halten 4 22,2%
- Verkauf 2 11,1%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
8 Analysten · 2026-08-16
Median
$5.00
Jetzt
$2.90
Tief
$1.00
Hoch
$15.00
Median-Ziel
$5.00
+72,4%
Mittelwert-Ziel
$6.00
+106,9%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.03%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.15 | $-0.28 | 0.13% |
| 31. März 2026 | $-0.26 | $-0.27 | 0.01% |
| 31. Dezember 2025 | $-0.06 | $-0.26 | 0.20% |
| 30. September 2025 | $-0.28 | $-0.30 | 0.02% |
| 30. Juni 2025 | $-0.63 | $-0.38 | -0.25% |
| 31. März 2025 | $-0.92 | $-0.60 | -0.32% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| BNTC | $307M | -11.1 | — | — | -43.8% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
| PROK | — | — | 1075.0% | -7725.2% | 6.9% | — |
| FENC | $263M | -22.6 | -6.1% | -21.8% | -69.6% | — |
| LXEO | $725M | -5.3 | — | — | -51.9% | — |
| CAPR | $1.66B | -12.8 | -11.6% | — | -51.1% | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Bilanz 24
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Cashflow 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Rentabilität 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Gewinn- und Verlustrechnung 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Bilanz 24
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Liquidität & Solvenz 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Bewertung (TTM) 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $41M | $32M | $78M | $20M | $26M |
| Betriebsgewinnmarge % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Nettoergebnis | $-160M | $-237M | $-153M | $-220M | $-193M |
| Verwässerte EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 2.1 | 0.4 | — | — | — |
| Liquiditätsgrad | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-166M | $-219M | $-137M | $-181M | $-172M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 239 Einreicher · $327.2M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 41 (+2 vs. Vorquartal) | 22 (-4 vs. Vorquartal) | 76 (+20 vs. Vorquartal) | 42 (-9 vs. Vorquartal) | +75.4M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.000.000 | 11.111.111 | 11,00% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $28.800.360 | 8.889.000 | 8,80% | Aktien |
| Commodore Capital LP | $28.800.360 | 8.889.000 | 8,80% | Aktien |
| ADAR1 Capital Management, LLC | $28.800.360 | 8.889.000 | 8,80% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.897.929 | 6.141.336 | 6,08% | Aktien |
| Paradigm Biocapital Advisors LP | $18.100.665 | 5.586.625 | 5,53% | Aktien |
| Opaleye Management Inc. | $12.512.653 | 3.861.930 | 3,82% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.658.618 | 3.598.339 | 3,56% | Aktien |
| Woodline Partners LP | $11.519.810 | 3.555.497 | 3,52% | Aktien |
| Vivo Capital, LLC | $11.519.010 | 3.555.250 | 3,52% | Aktien |
| GordonMD Global Investments LP | $10.131.480 | 3.127.000 | 3,10% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $7.999.298 | 2.468.919 | 2,45% | Aktien |
| Logos Global Management LP | $7.199.280 | 2.222.000 | 2,20% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $7.134.030 | 2.201.290 | 2,18% | Aktien |
| STATE STREET CORP | $7.101.442 | 2.191.803 | 2,17% | Aktien |
| GOLDMAN SACHS GROUP INC | $6.763.843 | 2.087.606 | 2,07% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $4.318.842 | 1.332.976 | 1,32% | Aktien |
| Seven Fleet Capital Management LP | $4.310.820 | 1.330.500 | 1,32% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $4.201.156 | 1.296.653 | 1,28% | Aktien |
| MARSHALL WACE, LLP | $4.044.048 | 1.248.163 | 1,24% | Aktien |
| D. E. Shaw & Co., Inc. | $3.715.178 | 1.146.660 | 1,14% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.344.111 | 1.032.133 | 1,02% | Aktien |
| MACKENZIE FINANCIAL CORP | $2.844.856 | 878.042 | 0,87% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.812.424 | 868.032 | 0,86% | Aktien |
| Nantahala Capital Management, LLC | $2.762.748 | 852.700 | 0,84% | Aktien |
| TWO SIGMA ADVISERS, LP | $2.509.405 | 1.224.100 | 0,77% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.407.158 | 742.950 | 0,74% | Aktien |
| BlackRock, Inc. | $1.813.920 | 559.852 | 0,55% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $1.616.750 | 498.997 | 0,49% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $1.545.801 | 477.099 | 0,47% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.521.180 | 469.500 | 0,46% | Kaufoption |
| Eversept Partners, LP | $1.486.541 | 458.809 | 0,45% | Aktien |
| Casdin Capital, LLC | $1.441.800 | 445.000 | 0,44% | Aktien |
| PEAK6 LLC | $1.346.029 | 415.441 | 0,41% | Aktien |
| DIADEMA PARTNERS LP | $1.296.000 | 400.000 | 0,40% | Kaufoption |
| BIT Capital GmbH | $1.056.240 | 326.000 | 0,32% | Aktien |
| Cubist Systematic Strategies, LLC | $994.094 | 286.482 | 0,30% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878.642 | 271.186 | 0,27% | Aktien |
| BANK OF AMERICA CORP /DE/ | $751.119 | 231.827 | 0,23% | Aktien |
| LPL Financial LLC | $748.813 | 231.115 | 0,23% | Aktien |
| Erste Asset Management GmbH | $736.000 | 230.000 | 0,22% | Aktien |
| IEQ CAPITAL, LLC | $705.623 | 217.785 | 0,22% | Aktien |
| Walleye Capital LLC | $595.703 | 183.859 | 0,18% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558.900 | 172.500 | 0,17% | Verkaufsoption |
| CITADEL ADVISORS LLC | $557.604 | 172.100 | 0,17% | Verkaufsoption |
| DAFNA Capital Management LLC | $552.323 | 170.470 | 0,17% | Aktien |
| Mariner, LLC | $548.500 | 169.291 | 0,17% | Aktien |
| Green Alpha Advisors, LLC | $505.589 | 156.046 | 0,15% | Aktien |
| PEAK6 LLC | $497.340 | 153.500 | 0,15% | Kaufoption |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490.555 | 151.406 | 0,15% | Aktien |
| BARCLAYS PLC | $476.030 | 146.923 | 0,15% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $464.187 | 187.930 | 0,14% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445.030 | 137.355 | 0,14% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408.240 | 126.000 | 0,12% | Aktien |
| Point72 Asset Management, L.P. | $405.758 | 125.234 | 0,12% | Aktien |
| RHUMBLINE ADVISERS | $380.421 | 117.417 | 0,12% | Aktien |
| JPMORGAN CHASE & CO | $376.528 | 117.665 | 0,12% | Aktien |
| JANE STREET GROUP, LLC | $374.473 | 115.578 | 0,11% | Aktien |
| FMR LLC | $348.384 | 107.526 | 0,11% | Aktien |
| HSBC HOLDINGS PLC | $314.481 | 97.062 | 0,10% | Aktien |
| Bank of New York Mellon Corp | $309.378 | 95.487 | 0,09% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $303.462 | 93.661 | 0,09% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300.818 | 92.845 | 0,09% | Aktien |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300.226 | 92.094 | 0,09% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $300.011 | 92.596 | 0,09% | Aktien |
| CWM, LLC | $259.352 | 105.001 | 0,08% | Aktien |
| MORGAN STANLEY | $237.324 | 73.248 | 0,07% | Aktien |
| CITADEL ADVISORS LLC | $229.392 | 70.800 | 0,07% | Kaufoption |
| OSAIC HOLDINGS, INC. | $222.928 | 68.806 | 0,07% | Aktien |
| SEI INVESTMENTS CO | $221.188 | 68.268 | 0,07% | Aktien |
| Nuveen, LLC | $221.188 | 68.268 | 0,07% | Aktien |
| Joel Isaacson & Co., LLC | $220.787 | 68.144 | 0,07% | Aktien |
| JANE STREET GROUP, LLC | $218.376 | 67.400 | 0,07% | Verkaufsoption |
| SIMPLEX TRADING, LLC | $207.275 | 63.974 | 0,06% | Aktien |
| MetLife Investment Management, LLC | $182.140 | 56.216 | 0,06% | Aktien |
| CITIGROUP INC | $182.052 | 56.189 | 0,06% | Aktien |
| CITADEL ADVISORS LLC | $173.923 | 53.680 | 0,05% | Aktien |
| MML INVESTORS SERVICES, LLC | $168.765 | 52.088 | 0,05% | Aktien |
| GROUP ONE TRADING LLC | $163.131 | 50.349 | 0,05% | Aktien |
| Creative Planning | $147.653 | 45.572 | 0,05% | Aktien |
| China Universal Asset Management Co., Ltd. | $143.934 | 44.424 | 0,04% | Aktien |
| WINTON GROUP Ltd | $141.588 | 43.700 | 0,04% | Aktien |
| Vanguard Global Advisers, LLC | $138.876 | 42.863 | 0,04% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $137.376 | 42.400 | 0,04% | Aktien |
| Graham Capital Management, L.P. | $134.369 | 41.472 | 0,04% | Aktien |
| Quinn Opportunity Partners LLC | $129.600 | 40.000 | 0,04% | Aktien |
| Invesco Ltd. | $128.178 | 39.561 | 0,04% | Aktien |
| Vanguard Personalized Indexing Management, LLC | $124.108 | 38.305 | 0,04% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $121.967 | 37.644 | 0,04% | Aktien |
| Balyasny Asset Management L.P. | $121.947 | 37.638 | 0,04% | Aktien |
| AXQ CAPITAL, LP | $118.104 | 36.452 | 0,04% | Aktien |
| Nuveen Asset Management, LLC | $113.934 | 89.712 | 0,03% | Aktien |
| SCS Capital Management LLC | $113.400 | 35.000 | 0,03% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $109.749 | 33.873 | 0,03% | Aktien |
| Thrive Wealth Management, LLC | $108.540 | 33.500 | 0,03% | Aktien |
| TWO SIGMA SECURITIES, LLC | $107.367 | 33.138 | 0,03% | Aktien |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102.359 | 31.207 | 0,03% | Aktien |
| CAPTRUST FINANCIAL ADVISORS | $98.159 | 30.296 | 0,03% | Aktien |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89.683 | 27.680 | 0,03% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88.339 | 27.265 | 0,03% | Aktien |
Unternehmensinsider 32 Insider · 13 Führungskräfte · 15 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3. Juni 2026 S | 248.313 | 0 | 1 | $-41.543 |
| MULLEN JAMES C | CEO | 3. Januar 2022 S | 75.898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9. Februar 2021 S | 43.760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8. Januar 2019 S | 1.204.966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11. Januar 2022 S | 31.462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4. Februar 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28. Juli 2026 S | 62.369 | 0 | 2 | $-15.133 |
| Bruce Eaton | EVP, Chief Business Officer | 22. Dezember 2021 A | 31.498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22. Dezember 2021 A | 22.675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22. Dezember 2021 A | 41.785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28. Oktober 2019 A | 25.000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18. März 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7. Februar 2018 A | 4.000 | 0 | 0 | $0 |
| Elliott M. Levy | Direktor | 17. Juni 2026 A | — | 0 | 0 | $0 |
| David Scadden | Direktor | 17. Juni 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Direktor | 17. Juni 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Direktor | 17. Juni 2026 A | 22.700 | 0 | 0 | $0 |
| Andrew Hirsch | Direktor | 17. Juni 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Direktor | 3. September 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Direktor | 3. Juni 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Direktor | 15. Juni 2018 A | 35.000 | 0 | 0 | $0 |
| Douglas G. Cole | Direktor | 17. August 2017 J | 3.171 | 0 | 0 | $0 |
| Kevin Bitterman | Direktor | 15. Juni 2017 A | 2.797.144 | 0 | 0 | $0 |
| Alexis Borisy | Direktor | 15. Juni 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Direktor | 15. Juni 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | 10%-Eigentümer | 6. September 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10%-Eigentümer | 8. Februar 2016 C | 2.649.572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 6. August 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 3. August 2026 S | 14.292 | 0 | 2 | $-3.002 |
| Akshay Vaishnaw | — | 3. Juni 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15. Dezember 2020 M | 24.907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15. März 2017 M | 117.788 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 Einreichungen | 18. September 2017 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 28 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,41% | 32.319 SH | 8. August 2026 | Täglich |
| GNOM · Global X Funds | 0,34% | 54.725 NS | 31. Mai 2026 | N-PORT |
| IWC · iShares Trust | 0,07% | 341.978 SH | 8. August 2026 | Täglich |
| IBB · iShares Trust | 0,03% | 1.035.067 SH | 8. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 8.268 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96.927 SH | 8. August 2026 | Täglich |
| BIB · ProShares Trust | 0,02% | 3.611 NS | 31. Mai 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1.527 NS | 31. Mai 2026 | N-PORT |
| IWO · iShares Trust | 0,02% | 823.535 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 118.938 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575.834 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 461.967 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 2.583.050 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 42.610 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4.633 NS | 31. Mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476.309 NS | 31. Mai 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3.622 NS | 31. Mai 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32.379 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3.660 NS | 31. Mai 2026 | N-PORT |
| IWN · iShares Trust | 0,00% | 120.119 SH | 8. August 2026 | Täglich |
| HDG · ProShares Trust | 0,00% | 92 NS | 31. Mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2.922 NS | 31. Mai 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96.350 NS | 31. Mai 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19.020 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1.100.306 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.890.144 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.046 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.608 SH | 8. August 2026 | Täglich |